Back
Test Evidence-Based Strategies for Selecting and Sequencing Systemic Therapies in RCC: Highlights From ASCO GU 2022 and Beyond
A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.
Test Evidence-Based Strategies for Selecting and Sequencing Systemic Therapies in RCC: Highlights From ASCO GU 2022 and Beyond
Episodes
All
All
Please check back later for more content.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Olaparib Maintenance Yields Promising Long-Term OS Outcomes in Asian Patients With Platinum-Sensitive, Relapsed Ovarian Cancer
5